PATENT CLAIM ANALYSIS

Application Number: 16006420
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "186100"]

Abstract:
The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

Claim (Index 2):
The isolated anti-HIV antibody of  claim 1 , or antigen binding portion thereof, wherein the CDR comprises a sequence selected from the group consisting of SEQ ID NOs: 39-104.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 94.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14436608', '15379157', '15918343', '15559791', '15115547']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7794866059487933
- 35 USC 102 Novelty (BERT): 0.6586079566503978
- Combined Prediction Score: 0.7673987410189538
- Mean Citation Score: 461.318914
- Max Citation Score: 724.87335
- Similarity Product: 586.8342594554989

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test